Codexis, Inc. CDXS
We take great care to ensure that the data presented and summarized in this overview for CODEXIS, INC. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding CDXS
View all-
Black Rock Inc. New York, NY6.61MShares$23.9 Million0.0% of portfolio
-
Nantahala Capital Management, LLC New Canaan, CT4.46MShares$16.1 Million1.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.26MShares$15.4 Million0.0% of portfolio
-
Baillie Gifford & CO3.45MShares$12.4 Million0.01% of portfolio
-
Opaleye Management Inc. Boston, MA3.12MShares$11.3 Million2.68% of portfolio
-
Telemark Asset Management, LLC Boston, MA2.7MShares$9.73 Million1.1% of portfolio
-
Casdin Capital, LLC New York, NY2MShares$7.22 Million0.56% of portfolio
-
Nuveen Asset Management, LLC Chicago, IL1.64MShares$5.93 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA1.56MShares$5.64 Million0.0% of portfolio
-
State Street Corp Boston, MA1.51MShares$5.46 Million0.0% of portfolio
Latest Institutional Activity in CDXS
Top Purchases
Top Sells
About CDXS
Codexis, Inc. discovers, develops, and sells enzymes and other proteins. It offers biocatalyst products and services; intermediate chemicals products that are used for further chemical processing; and Codex biocatalyst panels and kits that enable customers to perform chemistry screening. The company also provides biocatalyst screening and protein engineering services. In addition, it offers CodeEvolver protein engineering technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations and enhance the efficiency and productivity of manufacturing processes. The company's platform is also used to discover novel biotherapeutic drug candidates for targeted human diseases, as well as for molecular biology and in vitro diagnostic enzymes. It sells its products to pharmaceutical manufacturers through its direct sales and business development force in the United States and Europe. The company was incorporated in 2002 and is headquartered in Redwood City, California.
Insider Transactions at CDXS
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jan 01
2024
|
Stephen George Dilly |
BUY
Grant, award, or other acquisition
|
Direct |
143,425
+19.76%
|
-
|
|
Jan 01
2024
|
Margaret Nell Fitzgerald |
BUY
Grant, award, or other acquisition
|
Direct |
52,350
+28.13%
|
-
|
|
Jan 01
2024
|
Kevin Norrett Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
52,350
+25.81%
|
-
|
|
Jan 01
2024
|
Sriram Ryali Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
52,350
+22.95%
|
-
|
|
Nov 15
2023
|
Byron L Dorgan |
SELL
Open market or private sale
|
Direct |
20,000
-9.37%
|
$40,000
$2.11 P/Share
|
|
Sep 11
2023
|
Kevin Norrett Chief Operating Officer |
BUY
Open market or private purchase
|
Direct |
9,000
+8.4%
|
$9,000
$1.72 P/Share
|
|
Sep 08
2023
|
Stephen George Dilly |
BUY
Open market or private purchase
|
Direct |
58,479
+11.76%
|
$58,479
$1.73 P/Share
|
|
Sep 08
2023
|
Margaret Nell Fitzgerald |
BUY
Open market or private purchase
|
Direct |
11,834
+12.69%
|
$11,834
$1.7 P/Share
|
|
Sep 08
2023
|
Sriram Ryali Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
11,650
+8.62%
|
$11,650
$1.7 P/Share
|
|
Jun 13
2023
|
Dennis P Wolf |
BUY
Grant, award, or other acquisition
|
Direct |
34,602
+31.06%
|
-
|
|
Jun 13
2023
|
Esther Martinborough |
BUY
Grant, award, or other acquisition
|
Direct |
34,602
+37.39%
|
-
|
|
Jun 13
2023
|
Jennifer Aaker |
BUY
Grant, award, or other acquisition
|
Direct |
34,602
+34.32%
|
-
|
|
Jun 13
2023
|
David V Smith |
BUY
Grant, award, or other acquisition
|
Direct |
34,602
+50.0%
|
-
|
|
Jun 13
2023
|
David V Smith |
SELL
Bona fide gift
|
Direct |
11,273
-100.0%
|
-
|
|
Jun 13
2023
|
Rahul Singhvi |
BUY
Grant, award, or other acquisition
|
Direct |
34,602
+34.41%
|
-
|
|
Jun 13
2023
|
H Stewart Parker |
BUY
Grant, award, or other acquisition
|
Direct |
34,602
+32.31%
|
-
|
|
Jun 13
2023
|
Alison Moore |
BUY
Grant, award, or other acquisition
|
Direct |
34,602
+33.54%
|
-
|
|
Jun 13
2023
|
Byron L Dorgan |
BUY
Grant, award, or other acquisition
|
Direct |
34,602
+13.95%
|
-
|
|
Apr 18
2023
|
John J Nicols |
SELL
Open market or private sale
|
Direct |
35,714
-4.36%
|
$142,856
$4.14 P/Share
|
|
Apr 18
2023
|
John J Nicols |
BUY
Exercise of conversion of derivative security
|
Direct |
35,714
+4.18%
|
$35,714
$1.97 P/Share
|
Last 12 Months Summary
| Grant, award, or other acquisition | 577K shares |
|---|---|
| Open market or private purchase | 91K shares |
| Bona fide gift | 11.3K shares |
|---|---|
| Open market or private sale | 20K shares |